Drugs / TAK-186
TAK-186
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04844073 | Mar 2021 → Jun 2025 | colorectal cancer, head and neck squamous cell carcinoma, non-small cell lung carcinoma | Takeda | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-186 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04844073 ↗ |
| Known as | MVC-101 | “A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer” NCT04844073 ↗ |
| Known as | Tak-186 egfr targeted tce cobra | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315000 ↗ |
| Route | Intravenous | “TAK-186 IV infusion.” NCT04844073 ↗ |